MiR-1248: a new prognostic biomarker able to identify supratentorial hemispheric pediatric low-grade gliomas patients associated with progression.
Pediatric low-grade gliomas
Personalized medicine
Prognostic biomarker
Risk stratification
Tumour progression
miR-1248
Journal
Biomarker research
ISSN: 2050-7771
Titre abrégé: Biomark Res
Pays: England
ID NLM: 101607860
Informations de publication
Date de publication:
17 Jun 2022
17 Jun 2022
Historique:
received:
07
04
2022
accepted:
01
06
2022
entrez:
17
6
2022
pubmed:
18
6
2022
medline:
18
6
2022
Statut:
epublish
Résumé
Pediatric low-grade gliomas (pLGGs), particularly incompletely resected supratentorial tumours, can undergo progression after surgery. However to date, there are no predictive biomarkers for progression. Here, we aimed to identify pLGG-specific microRNA signatures and evaluate their value as a prognostic tool. We identified and validated supratentorial incompletey resected pLGG-specific microRNAs in independent cohorts from four European Pediatric Neuro-Oncology Centres. These microRNAs demonstrated high accuracy in differentiating patients with or without progression. Specifically, incompletely resected supratentorial pLGGs with disease progression showed significantly higher miR-1248 combined with lower miR-376a-3p and miR-888-5p levels than tumours without progression. A significant (p < 0.001) prognostic performance for miR-1248 was reported with an area under the curve (AUC) of 1.00. We also highlighted a critical oncogenic role for miR-1248 in gliomas tumours. Indeed, high miR-1248 levels maintain low its validated target genes (CDKN1A (p21)/FRK/SPOP/VHL/MTAP) and consequently sustain the activation of oncogenic pathways. Altogether, we provide a novel molecular biomarker able to successfully identify pLGG patients associated with disease progression that could support the clinicians in the decision-making strategy, advancing personalized medicine.
Sections du résumé
BACKGROUND
BACKGROUND
Pediatric low-grade gliomas (pLGGs), particularly incompletely resected supratentorial tumours, can undergo progression after surgery. However to date, there are no predictive biomarkers for progression. Here, we aimed to identify pLGG-specific microRNA signatures and evaluate their value as a prognostic tool.
METHODS
METHODS
We identified and validated supratentorial incompletey resected pLGG-specific microRNAs in independent cohorts from four European Pediatric Neuro-Oncology Centres.
RESULTS
RESULTS
These microRNAs demonstrated high accuracy in differentiating patients with or without progression. Specifically, incompletely resected supratentorial pLGGs with disease progression showed significantly higher miR-1248 combined with lower miR-376a-3p and miR-888-5p levels than tumours without progression. A significant (p < 0.001) prognostic performance for miR-1248 was reported with an area under the curve (AUC) of 1.00. We also highlighted a critical oncogenic role for miR-1248 in gliomas tumours. Indeed, high miR-1248 levels maintain low its validated target genes (CDKN1A (p21)/FRK/SPOP/VHL/MTAP) and consequently sustain the activation of oncogenic pathways.
CONCLUSIONS
CONCLUSIONS
Altogether, we provide a novel molecular biomarker able to successfully identify pLGG patients associated with disease progression that could support the clinicians in the decision-making strategy, advancing personalized medicine.
Identifiants
pubmed: 35715818
doi: 10.1186/s40364-022-00389-x
pii: 10.1186/s40364-022-00389-x
pmc: PMC9205050
doi:
Types de publication
Journal Article
Langues
eng
Pagination
44Informations de copyright
© 2022. The Author(s).
Références
J Clin Lab Anal. 2020 Oct;34(10):e23433
pubmed: 32608539
Klin Padiatr. 2019 May;231(3):107-135
pubmed: 31108561
Nat Genet. 2013 Aug;45(8):927-32
pubmed: 23817572
Med Sci Monit. 2019 Jul 22;25:5435-5444
pubmed: 31328722
Nature. 2016 Jan 14;529(7585):172-7
pubmed: 26735018
Elife. 2017 Oct 20;6:
pubmed: 29053101
Pathobiology. 2015;82(2):84-9
pubmed: 26088413
Int J Oncol. 2015 Jan;46(1):333-41
pubmed: 25351530
Nat Rev Cancer. 2019 Aug;19(8):420-438
pubmed: 31300807
Nature. 2014 Jun 26;510(7506):537-41
pubmed: 24847876
Nucleic Acids Res. 2019 Jan 8;47(D1):D155-D162
pubmed: 30423142
Sci Rep. 2018 Aug 21;8(1):12506
pubmed: 30131528
Neurosurgery. 2011 Jun;68(6):1548-54; discussion 1554-5
pubmed: 21368693
Childs Nerv Syst. 2016 Nov;32(11):2061-2067
pubmed: 27613640
Cancer Gene Ther. 2006 Apr;13(4):428-35
pubmed: 16211089
J Neurooncol. 2012 Oct;110(1):9-19
pubmed: 22790444
Neuropathol Appl Neurobiol. 2018 Dec;44(7):687-706
pubmed: 29478280
Genet Mol Biol. 2018 Jan-Mar;41(1):27-34
pubmed: 29658967
Acta Neuropathol. 2018 Oct;136(4):641-655
pubmed: 29948154
Neuro Oncol. 2018 Jan 22;20(2):160-173
pubmed: 29016845
PLoS One. 2011;6(9):e24248
pubmed: 21912681
Nucleic Acids Res. 2020 Jan 8;48(D1):D148-D154
pubmed: 31647101
Acta Neuropathol Commun. 2019 Feb 20;7(1):24
pubmed: 30786920
J Mol Neurosci. 2015 Jan;55(1):32-41
pubmed: 24969324
Neuro Oncol. 2013 Jan;15(1):69-82
pubmed: 23161775
Neuro Oncol. 2013 Dec;15(12):1604-14
pubmed: 24203892
J Clin Oncol. 2017 Jul 20;35(21):2370-2377
pubmed: 28640698
Onco Targets Ther. 2020 Jun 17;13:5709-5719
pubmed: 32606783
Neuropathol Appl Neurobiol. 2021 Feb;47(1):96-107
pubmed: 32603552
Nucleic Acids Res. 2013 Jan;41(Database issue):D970-6
pubmed: 23066107
Acta Neuropathol Commun. 2015 Dec 18;3:86
pubmed: 26682910
Neuro Oncol. 2012 Sep;14(9):1146-52
pubmed: 22753230
Nature. 2018 Mar 22;555(7697):469-474
pubmed: 29539639
Pulm Pharmacol Ther. 2020 Oct;64:101949
pubmed: 32949706
Cell Physiol Biochem. 2018;45(4):1581-1589
pubmed: 29482191
Neuro Oncol. 2021 Oct 1;23(10):1634-1646
pubmed: 34131743
Mod Pathol. 2017 Feb;30(2):204-216
pubmed: 27739438
Nat Biotechnol. 2008 Apr;26(4):462-9
pubmed: 18362881
Oncotarget. 2018 Jun 15;9(46):28103-28115
pubmed: 29963264
Signal Transduct Target Ther. 2016 Jan 28;1:15004
pubmed: 29263891
Cancer Cell. 2020 Apr 13;37(4):569-583.e5
pubmed: 32289278
Brain. 2019 Jan 1;143(1):131-149
pubmed: 31834371
BMC Cancer. 2018 Dec 17;18(1):1259
pubmed: 30558563
Cancer Manag Res. 2020 Apr 21;12:2653-2662
pubmed: 32368143
Neuro Oncol. 2012 Aug;14(8):1026-36
pubmed: 22649212
Neuro Oncol. 2021 Aug 2;23(8):1231-1251
pubmed: 34185076
Neuro Oncol. 2019 Aug 5;21(8):968-980
pubmed: 30805642
Pediatr Blood Cancer. 2011 Feb;56(2):211-6
pubmed: 21157891
Biochem Biophys Res Commun. 2019 Oct 1;517(4):588-595
pubmed: 31395336
BMC Med Genomics. 2020 Sep 18;13(Suppl 8):129
pubmed: 32948204
Cells. 2020 Jan 23;9(2):
pubmed: 31979244
J Clin Oncol. 2012 Jul 20;30(21):2641-7
pubmed: 22665535
Biomed Res Int. 2020 Jul 1;2020:1980921
pubmed: 32714975
Biol Direct. 2013 Apr 24;8:10
pubmed: 23618224
Cancer Cell. 2020 Apr 13;37(4):424-425
pubmed: 32289265
J Clin Oncol. 2015 Sep 20;33(27):2986-98
pubmed: 26304884
Nat Rev Cancer. 2009 Jun;9(6):400-14
pubmed: 19440234